TITLE

Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial

AUTHOR(S)
Duffy, N.; Walker, P.; Diamantea, F.; Calverley, P. M. A.; Davies, L.
PUB. DATE
September 2005
SOURCE
Thorax;Sep2005, Vol. 60 Issue 9, p713
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Intravenous aminophylline is commonly used in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD), despite limited evidence for its efficacy and known risks of toxicity. We hypothesised that adding intravenous aminophylline to conventional treatment would not produce clinically important changes in the speed of spirometric or symptomatic recovery or shorten hospital stay in patients with exacerbations of COPD. Methods: Eighty patients admitted to hospital with non-acidotic exacerbations of COPD were recruited at admission to a randomised, double blind, placebo controlled study comparing intravenous aminophylline 0.5 mg/kg/hour after an appropriate loading dose with an equivalent volume of 0.9% saline. The primary outcome was the change in post-bronchodilator forced expiratory volume in 1 second (FEV1) over the first 5 days of the admission. Secondary end points were changes in self-reported breathlessness, arterial blood gas tensions, forced vital capacity (FYC), and length of hospital stay. Results: There was no difference in the post-bronchodilator FEV1 over the first 5 days between the aminophylline and placebo groups. In the aminophylline group, 2 hours of treatment produced a small but significant rise in arterial pH (p = 0.001) and a fall in arterial carbon dioxide tension (p = 0.01) compared with placebo treatment. There were no differences in the severity of breathlessness, post-bronchodilator FVC, or length of hospital stay between the groups. Nausea was a more frequent side effect in the aminophylline group (46% v 22%; p<.05), but palpitations and headache were noted equally in both groups. Conclusions: Although intravenous aminophylline produced small improvements in acid-base balance, these did not influence the subsequent clinical course. No evidence was found for any clinically important additional effect of aminophylline treatment when used with high dose nebulised bronchodilators and oral corticosteroids. Given its known toxicity, we cannot therefore recommend the use of intravenous aminophylline in the treatment of non-acidotic COPD exacerbations.
ACCESSION #
18366920

 

Related Articles

  • The "Towards a Revolution in COPD Health" study. D'Urzo, Anthony D. // Canadian Family Physician;May2008, Vol. 54, p740 

    The article considers whether salmeterol and fluticasone propionate combination reduces all-cause mortality compared with placebo in patients with chronic obstructive pulmonary disease. According to the author, treatment with salmeterol and fluticasone propionate combination does not...

  • Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Fuld, J. P.; Kilduff, L. P.; Neder, J. A.; Pitsiladis, Y.; Lean, M. E. J.; Ward, S. A.; Cotton, M. M. // Thorax;Jul2005, Vol. 60 Issue 7, p531 

    Background: Skeletal muscle wasting and dysfunction are strong independent predictors of mortality in patients with chronic obstructive pulmonary disease (COPD). Creatine nutritional supplementation produces increased muscle mass and exercise performance in health. A controlled...

  • Beta-blocker use and COPD mortality: a systematic review and meta-analysis. Etminan, Mahyar; Jafari, Siavash; Carleton, Bruce; FitzGerald, John Mark // BMC Pulmonary Medicine;2012, Vol. 12 Issue 1, p48 

    Background: Despite the benefits of beta-blockers in patients with established or sub-clinical coronary artery disease, their use in patients with chronic obstructive pulmonary disease (COPD) has been controversial. Currently, no systematic review has examined the impact of beta-blockers on...

  • Singing classes for chronic obstructive pulmonary disease: a randomized controlled trial. Lord, Victoria M.; Hume, Victoria J.; Kelly, Julia L.; Cave, Phoene; Silver, Judith; Waldman, Maya; White, Chris; Smith, Cayley; Tanner, Rebecca; Sanchez, Melissa; Man, William D-C.; Polkey, Michael I.; Hopkinson, Nicholas S. // BMC Pulmonary Medicine;2012, Vol. 12 Issue 1, p69 

    Background: There is some evidence that singing lessons may be of benefit to patients with chronic obstructive pulmonary disease (COPD). It is not clear how much of this benefit is specific to singing and how much relates to the classes being a group activity that addresses social isolation....

  • Effectiveness and cost-effectiveness of early assisted discharge for Chronic Obstructive Pulmonary Disease exacerbations: the design of a randomised controlled trial. Utens, Cecile M. A.; Goossens, Lucas M. A.; Smeenk, Frank W. J. M.; van Schayck, Onno C. P.; van Litsenburg, Walter; Janssen, Annet; van Vliet, Monique; Seezink, Wiel; Demunck, Dirk R. A. J.; van de Pas, Brigitte; de^Bruijn, Peter J.; van der Pouw, Anouschka; Retera, Jeroen M. A. M.; de Laat-Bierings, Petra; van Eijsden, Loes; Braken, Maria; Eijsermans, Riet; Mölken, Maureen P. M. H. Rutten-van // BMC Public Health;2010, Vol. 10 Issue 1, p618 

    Background: Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are the main cause for hospitalisation. These hospitalisations result in a high pressure on hospital beds and high health care costs. Because of the increasing prevalence of COPD this will only become worse. Hospital at...

  • Independent Nurse: COPD - Clinical Respiratory - The role of mucolytics in COPD. Booker, Rachel // GP: General Practitioner;2/24/2006, p97 

    The article presents information on the role of mucolytics in COPD. Patients with COPD may benefit from mucolytics. The efficiency of mucociliary clearance depends on the volume of mucus produced, mucus viscosity, and whether the structures of the mucociliary escalator are intact. Many patients...

  • Cost-Effectiveness of Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. Oba, Yuji // Mayo Clinic Proceedings;May2007, Vol. 82 Issue 5, p575 

    OBJECTIVE: To evaluate and compare the cost-effectiveness of long-acting bronchodilators by estimating incremental costs per quality-adjusted life-year (QALY) gained in patients with moderate to severe chronic obstructive pulmonary disease. METHODS: This cost-effective analysis was conducted...

  • A review of bronchodilators for chronic obstructive pulmonary disease. Smith, Haley // South African Pharmaceutical Journal;2013, Vol. 80 Issue 7, p9 

    Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is associated with airway obstruction. COPD is a major cause of chronic morbidity and mortality throughout the world. It is a progressive condition, but is partially reversible through treatment, especially when...

  • COMMENTARY. Niewoehner, Dennis E. // Evidence Based Medicine;Oct2008, Vol. 13 Issue 5, p145 

    The article focuses on the adequacy and efficiency of oral corticosteroid therapy and intravenous (IV) therapy in patients with chronic obstructive pulmonary disease (COPD) exacerbations. It notes that those patients hospitalised with COPD prefer to use oral therapy. It states that there is no...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics